New guidance from health technology assessment (HTA) agency NICE backs the use of Wainzua (eplontersen) to treat stage 1 or 2 ...
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
Zacks.com on MSN21h
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra UseALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
Don't Miss our Black Friday Offers: Mani Foroohar has given his Buy rating due to a combination of factors including the recent FDA approval of BridgeBio Pharma’s drug Attruby for treating ...
Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...
Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary ...
Leerink Partners analyst Mani Foroohar has maintained their neutral stance on ALNY stock, giving a Hold rating on November 25.Don't Miss our ...
Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary ...
A recent diagnosis didn't stop Don Amundson, of Bagley, from donning orange and participating in his favorite pastime: deer ...
Kronos is cutting 83% of its workforce, while Idorsia is considering cutting as many as 270 jobs. Elsewhere, PTC disclosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback